Amundi
UTHR icon

Amundi’s United Therapeutics UTHR Stock Holding History

Amundi’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119M Buy
219,094
+71,495
+48% +$40.3M 0.03% 419
2026
Q1 		$87.5M Sell
147,599
-15,595
-10% -$7.77M 0.02% 480
2025
Q4 		$79.5M Buy
163,194
+33,209
+26% +$15.5M 0.02% 535
2025
Q3 		$58.9M Sell
129,985
-232,841
-64% -$78.3M 0.02% 523
2025
Q2 		$107M Buy
362,826
+12,633
+4% +$3.78M 0.04% 399
2025
Q1 		$108M Buy
350,193
+232,988
+199% +$79.8M 0.04% 384
2024
Q4 		$43M Buy
117,205
+51,885
+79% +$19.1M 0.01% 587
2024
Q3 		$23.2M Sell
65,320
-407,672
-86% -$138M 0.01% 687
2024
Q2 		$147M Buy
472,992
+307,962
+187% +$81.5M 0.06% 292
2024
Q1 		$39.1M Sell
165,030
-24,434
-13% -$5.51M 0.02% 574
2023
Q4 		$42.5M Buy
189,464
+48,150
+34% +$11.1M 0.02% 566
2023
Q3 		$32.9M Buy
141,314
+87,931
+165% +$20.3M 0.02% 600
2023
Q2 		$11.9M Buy
53,383
+28,161
+112% +$6.24M 0.01% 806
2023
Q1 		$5.88M Sell
25,222
-4,471
-15% -$1.1M ﹤0.01% 962
2022
Q4 		$7.83M Buy
29,693
+28,146
+1,819% +$7.11M ﹤0.01% 904
2022
Q3 		$328K Buy
1,547
+18
+1% +$4.02K ﹤0.01% 1402
2022
Q2 		$363K Sell
1,529
-204
-12% -$41.5K ﹤0.01% 1304
2022
Q1 		$329K Sell
1,733
-147
-8% -$28K ﹤0.01% 1332
2021
Q4 		$391K Hold
1,880
– – ﹤0.01% 1419
2021
Q3 		$347K Hold
1,880
– – ﹤0.01% 1390
2021
Q2 		$337K Buy
+1,880
New +$358K ﹤0.01% 1308

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Amundi's UTHR Position: Q2 2026 in Review

Amundi increased its United Therapeutics (UTHR) stake by 48% in Q2 2026, buying an estimated $40.3M and bringing the position to 219,094 shares worth $119M. The position accounts for 0.03% of the portfolio, ranked #419.

Amundi first reported a position in UTHR in Q2 2021 and has held it in 21 quarters since. The position peaked at $147M in Q2 2024. 879 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Amundi held 219,094 shares of United Therapeutics worth $119M as of Q2 2026.
  • Amundi bought 71,495 United Therapeutics shares in Q2 2026, an estimated $40.3M.
  • United Therapeutics made up 0.03% of Amundi's portfolio in Q2 2026, its #419 holding.
  • Amundi first reported a position in United Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Amundi's United Therapeutics position peaked at $147M in Q2 2024.
  • 879 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.